ACADEMIA

SGLT-2 Inhibitors “Suited to Patients with Tendency to Obesity”: Prof. Kadowaki of Univ. of Tokyo

February 4, 2014
Speaking at a seminar held in Tokyo by Astellas Pharma on January 31, Takashi Kadowaki, professor at the Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, University of Tokyo, stated that glucose co-transporter-2 (SGLT-2) inhibitors, which are expected…

To read the full story

ACADEMIA

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…